Uitdehaag BM - Search Results

1

Intracellular cytokine profile in T-cell subsets of multiple sclerosis patients: different features in primary progressive disease.

Killestein J, Den Drijver BF, Van der Graaff WL, Uitdehaag BM, Polman CH, Van Lier RA. Killestein J, et al. Among authors: uitdehaag bm. Mult Scler. 2001 Jun;7(3):145-50. doi: 10.1177/135245850100700302. Mult Scler. 2001. PMID: 11475436

2

Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis.

van Lierop ZY, Wieske L, Koel-Simmelink MJ, Chatterjee M, Dekker I, Leurs CE, Willemse EA, Moraal B, Barkhof F, Eftimov F, Uitdehaag BM, Killestein J, Teunissen CE. van Lierop ZY, et al. Among authors: uitdehaag bm. Mult Scler. 2022 Jan;28(1):102-110. doi: 10.1177/13524585211010097. Epub 2021 Apr 23. Mult Scler. 2022. PMID: 33890520 Free PMC article.

3

Mediators of apoptosis Fas and FasL predict disability progression in multiple sclerosis over a period of 10 years.

Lopatinskaya L, Zwemmer J, Uitdehaag B, Lucas K, Polman C, Nagelkerken L. Lopatinskaya L, et al. Mult Scler. 2006 Dec;12(6):704-9. doi: 10.1177/1352458506070826. Mult Scler. 2006. PMID: 17262997 Clinical Trial.

4

Seasonal variation in immune measurements and MRI markers of disease activity in MS.

Killestein J, Rep MH, Meilof JF, Adèr HJ, Uitdehaag BM, Barkhof F, van Lier RA, Polman CH. Killestein J, et al. Among authors: uitdehaag bm. Neurology. 2002 Apr 9;58(7):1077-80. doi: 10.1212/wnl.58.7.1077. Neurology. 2002. PMID: 11940696

5

Multiple sclerosis functional composite: impact of reference population and interpretation of changes.

Uitdehaag BM, Adèr HJ, Roosma TJ, de Groot V, Kalkers NF, Polman CH. Uitdehaag BM, et al. Mult Scler. 2002 Oct;8(5):366-71. doi: 10.1191/1352458502ms835oa. Mult Scler. 2002. PMID: 12356201

6

Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue.

Kalkers NF, Vrenken H, Uitdehaag BM, Polman CH, Barkhof F. Kalkers NF, et al. Among authors: uitdehaag bm. Mult Scler. 2002 Oct;8(5):410-4. doi: 10.1191/1352458502ms833oa. Mult Scler. 2002. PMID: 12356208

7

Baseline T cell reactivity in multiple sclerosis is correlated to efficacy of interferon-beta.

Killestein J, Hintzen RQ, Uitdehaag BM, Baars PA, Roos MT, van Lier RA, Polman CH. Killestein J, et al. Among authors: uitdehaag bm. J Neuroimmunol. 2002 Dec;133(1-2):217-24. doi: 10.1016/s0165-5728(02)00373-9. J Neuroimmunol. 2002. PMID: 12446026

8

Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis.

Eikelenboom MJ, Killestein J, Izeboud T, Kalkers NF, van Lier RA, Barkhof F, Uitdehaag BM, Polman CH. Eikelenboom MJ, et al. Among authors: uitdehaag bm. J Neuroimmunol. 2002 Dec;133(1-2):225-32. doi: 10.1016/s0165-5728(02)00374-0. J Neuroimmunol. 2002. PMID: 12446027

9

The patient's perception of a (reliable) change in the Multiple Sclerosis Functional Composite.

Hoogervorst EL, Kalkers NF, Cutter GR, Uitdehaag BM, Polman CH. Hoogervorst EL, et al. Among authors: uitdehaag bm. Mult Scler. 2004 Feb;10(1):55-60. doi: 10.1191/1352458504ms972oa. Mult Scler. 2004. PMID: 14760953

10

No major association of ApoE genotype with disease characteristics and MRI findings in multiple sclerosis.

Zwemmer JN, van Veen T, van Winsen L, van Kamp GJ, Barkhof F, Polman CH, Uitdehaag BM. Zwemmer JN, et al. Among authors: uitdehaag bm. Mult Scler. 2004 Jun;10(3):272-7. doi: 10.1191/1352458504ms1010oa. Mult Scler. 2004. PMID: 15222690

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

434 results

Search Page

Filters